
The advantages of a risk-based approach to instrument replacement are discussed.
Douglas J. Turk is Business Unit Manager of Eurofins BioPharma Product Testing in Toronto, Canada. Doug has over 30 years of experience in pharmaceutical R&D and analytical testing in both large pharma and contract research organizations. Doug received a Doctor of Philosophy degree in analytical neurochemistry from the University of Oklahoma in Norman, Oklahoma, USA, as well as a B.Sc. degree (honours) in chemistry and an M.Sc. degree in analytical chemistry, both from McGill University in Montreal, Canada.

The advantages of a risk-based approach to instrument replacement are discussed.